Profile
NeoSci Ventures is a biotech venture builder based in Singapore, founded by Daphne Teo and Dr. Timothy Lu. They operate across Singapore, Taiwan, and the US, leveraging their extensive network in the biotech industry. The team comprises individuals with 15 years of experience in building and investing in biotech companies, contributing to businesses that have raised billions of dollars and achieved multiple public listings and acquisitions. NSV also operates NSG BioLabs, a co-working laboratory platform in Singapore for biotechnology companies.
NeoSci Ventures focuses on investing in biotechnology and healthcare companies, particularly in therapeutic candidates and technologies at the intersection of biology, artificial intelligence, data, and scientific tools. They target companies in the US and Asia, engaging with assets that aim to replenish pharmaceutical groups' pipelines. With a capital deployment strategy in place, NSV partakes in the early stages to bring potential discoveries into market-ready products. Their total assets under management include the newly launched Biotech Ventures Fund of $53 million.
Some of the notable portfolio companies include Protuoso, co-founded by NSV to develop protein-based therapeutics for complex diseases. Though not all investments are publicly disclosed, their strategic focus remains within their sphere of expertise in the biotechnology and healthcare sectors.
Industry
NeoSci Ventures Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Debut Biotech Fund
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
AI
|
Seed
Series A
|
North America
Asia
|
$1-5 m
|
$53 M
|
November 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.